Article Information
History
- October 4, 2021.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license.
Author Information
- 1Medical Affairs, GlaxoSmithKline pharmaceuticals Nigeria
- 2Medical Affairs, Vaccine, Global Public Health, Johnson & Johnson Pharmaceuticals
- 3College of Public Health, East Tennessee State University, Johnson City, United States
- ↵*Corresponding Author: Soyemi Kehinde Victor, email:Kehinde.v.soyemi{at}gsk.com